Dianthus Therapeutics, Inc.
DNTHNasdaqCIK 1690585HealthcareFiscal year ends Dec 31
Reports and events: 152 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0416:08 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001690585-26-000034 |
| 2026-08-0416:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001690585-26-000033 |
| 2026-06-1207:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001690585-26-000029 |
| 2026-05-2216:10 ET | 8-K | 5.07 Shareholder vote results | 0001690585-26-000026 |
| 2026-05-0516:06 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001690585-26-000022 |
| 2026-05-0516:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001690585-26-000021 |
| 2026-04-0916:09 ET | DEF 14A | Proxy statementPeriod 2026-05-21 | 0001690585-26-000012 |
| 2026-03-2608:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001690585-26-000010 |
| 2026-03-1207:20 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-103053 |
| 2026-03-0907:21 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001690585-26-000006 |
| 2026-03-0907:19 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events | 0001193125-26-097555 |
| 2026-01-1209:01 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-009898 |
| 2025-11-2521:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-116119 |
| 2025-11-1921:15 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000919574-25-007115 |
| 2025-11-0516:09 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-266920 |
| 2025-11-0516:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-266867 |
| 2025-11-0313:04 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-262188 |
| 2025-10-1608:00 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-240858 |
| 2025-09-1516:15 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-090015 |
| 2025-09-1107:20 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-200715 |
| 2025-09-0808:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-197751 |
| 2025-08-0716:11 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-105030 |
| 2025-08-0716:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-105002 |
| 2025-05-2216:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000950170-25-076304 |
| 2025-05-1216:14 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-069226 |
| 2025-05-1216:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-069195 |
| 2025-04-1016:31 ET | DEF 14A | Proxy statementPeriod 2025-05-22 | 0000950170-25-052874 |
| 2025-03-1921:30 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000919574-25-002011 |
| 2025-03-1116:06 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-037131 |
| 2025-03-1116:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-037125 |
| 2025-03-0507:16 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-25-033075 |
| 2024-12-1216:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-135775 |
| 2024-12-0321:19 ET | SC 13D/A | Ownership report, active investor, amended | 0000919574-24-006998 |
| 2024-11-0716:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123285 |
| 2024-11-0716:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-123255 |
| 2024-09-1616:06 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-106820 |
| 2024-09-1220:45 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-099432 |
| 2024-08-0816:10 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093948 |
| 2024-08-0816:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093920 |
| 2024-06-0608:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-069675 |
| 2024-05-2817:20 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-065371 |
| 2024-05-0916:20 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-057022 |
| 2024-05-0916:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056925 |
| 2024-04-1116:05 ET | DEF 14A | Proxy statementPeriod 2024-05-23 | 0000950170-24-043693 |
| 2024-04-0118:34 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-083707 |
| 2024-03-2117:02 ET | S-1/A | Registration statement, amended | 0001193125-24-073956 |
| 2024-03-2116:07 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-034681 |
| 2024-03-2116:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-034667 |
| 2024-02-0716:52 ET | S-1/A | Registration statement, amended | 0001193125-24-026760 |
| 2024-01-3112:11 ET | SC 13D | Ownership report, active investor | 0000919574-24-000598 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 11:27 ET. Listed shows no prices and gives no investment advice.